Cell-permeable dynamin I and dynamin II inhibitor (IC50 values are 1.9 and 4.4 μM for inhibition of dynamin I and II GTPase, respectively). Targets the pleckstrin homology (PH) (lipid binding) domain. Competitive with phospholipid and non-competitive with GTP. Inhibits receptor-mediated endocytosis (IC50 = 6.7 μM). Inhibits cancer cell growth.
Sold under exclusive licence from Children's Medical Research Institute and Newcastle Innovation Ltd. OcTMAB™ is a trademark of Children's Medical Research Institute and Newcastle Innovation Ltd.
Store at Room Temperature. Store under desiccating conditions. The product can be stored for up to 12 months.
Soluble in DMSO to 25 mM (with warming)
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
Functional Studies - OcTMAB™ (ab120467)
ab66705 staining PAI1 in HeLa cells treated with OcTMAB™ (ab120467), by ICC/IF. Increase in PAI1 expression correlates with increased concentration of OcTMAB™, as described in literature. The cells were incubated at 37°C for 24h in media containing different concentrations of ab120467 (OcTMAB™) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab66705 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Joshi S et al. The dynamin inhibitors MiTMAB and OcTMAB induce cytokinesis failure and inhibit cell proliferation in human cancer cells. Mol Cancer Ther9:1995-2006 (2010).
Read more (PubMed: 20571068) »
Quan A et al. Myristyl trimethyl ammonium bromide and octadecyl trimethyl ammonium bromide are surface-active small molecule dynamin inhibitors that block endocytosis mediated by dynamin I or dynamin II. Mol Pharmacol72:1425-39 (2007).
Read more (PubMed: 17702890) »